Sanofi

Sanofi (EPA:SAN), formerly Sanofi-Aventis, is a leading global healthcare company headquartered in Paris involved in the research, production, and distribution of pharmaceutical products. The company has been listed on Euronext Paris since May 1999, while its American Depositary Shares (ADS) have been listed on the Nasdaq since January 2019. Sanofi generated EUR 43.0 billion (~USD 45 billion) in revenue in 2022 and was ranked eighth among global pharmaceutical companies (based on revenue). 

Sanofi operates through three main segments: 1) Pharmaceuticals, which includes commercial operations of global franchises such as Specialty Care and General Medicines; 2) Vaccines ; and 3) Consumer Healthcare, which includes a range of products for allergy, cough and cold, pain, digestive, nutritional, etc. As of December 2023, Sanofi’s R&D pipeline included 79 clinical-stage projects, 23 of which are in Phase III or have been submitted to regulatory authorities for approval.  

The US constituted Sanofi’s largest market in 2022, contributing ~43% of the total revenue. In October 2023, Sanofi announced plans to spin out its Consumer Healthcare division, aiming to enhance focus and resource allocation for the Biopharma business. Sanofi is targeting EUR 22 billion in sales in immunology and over EUR 10 billion in sales in vaccines by 2030. Dupixent sales (the company’s largest product) are slated to grow at a low double-digit CAGR over 2023–2030. The company is also expecting to launch three to five new products, each with a EUR 2 billion–5 billion peak sales potential between 2025 and 2030. The company is committed to reaching net-zero emissions by 2045.